STOCK TITAN
  1. Home
  2. News
  3. SVRA

Savara Inc - SVRA STOCK NEWS

Welcome to our dedicated news page for Savara (Ticker: SVRA), a resource for investors and traders seeking the latest updates and insights on Savara.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Savara's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Savara's position in the market.

News
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Rhea-AI Summary
Savara Inc. announces data presentation at ATS 2024 on aPAP diagnosis and laboratory blood test development. Trillium Health to present on GM-CSF antibodies test. Abstracts to be published in AJRCCM supplement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
conferences
-
News
Savara Announces New Employment Inducement Grant
Rhea-AI Summary
Savara Inc. (SVRA) grants inducement awards to two new employees, consisting of options to purchase 125,000 shares and 70,000 restricted stock units (RSUs). The awards were granted under the 2021 Inducement Equity Incentive Plan. Options have a 10-year term with an exercise price of $4.89 per share, while RSUs vest over one to two years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
-
News
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Savara Inc. (SVRA) remains on track to report top-line data from the pivotal Phase 3 IMPALA-2 trial by the end of the second quarter of 2024. The 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease. The company anticipates filing a Biologics License Application (BLA) in the first half of 2025 pending the outcome of the IMPALA-2 trial. With approximately $162 million in cash and short-term investments, Savara believes it is sufficiently capitalized into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
earnings
News
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
Rhea-AI Summary
Savara Inc. (SVRA) will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference. The event will be live webcasted and archived for 90 days on Savara's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
conferences
-
News
Savara Announces New Employment Inducement Grant
Rhea-AI Summary
Savara Inc. (SVRA) announced the grant of inducement awards to a new employee, including options to purchase 70,000 shares of the company's common stock and restricted stock units (RSUs) covering 30,000 shares. The options have an exercise price of $4.94 per share and a 10-year term, while the RSUs vest in full on the two-year anniversary of the employee’s first day of employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.15%
Tags
none
-
News
Savara to Present at Two Upcoming Healthcare Conferences
Rhea-AI Summary
Savara Inc. (SVRA) will be participating in the Guggenheim 6th Annual Biotechnology Conference on February 7, 2024, and the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The company will be holding a fireside chat and a corporate presentation, respectively. Both presentations will be available via webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
conferences
News
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Rhea-AI Summary
Savara Inc. (Nasdaq: SVRA) has launched a new serum-based blood test, aPAP ClearPath™, for physicians in the U.S. to diagnose a rare autoimmune lung disease. The test is highly sensitive and specific, targeting GM-CSF autoantibodies, with an estimated diagnosed prevalence of seven cases per million in the U.S. The Company has partnered with Trillium Health to develop the test and has also launched a disease awareness campaign.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.76%
Tags
none
-
News
Savara Added to the NASDAQ Biotechnology Index
Rhea-AI Summary
Savara Inc. (SVRA) was added to the NASDAQ Biotech Index (NBI), effective December 18, 2023. The index tracks biotechnology and pharmaceutical securities listed on the Nasdaq Stock Market. Companies must meet eligibility requirements, including minimum market capitalization and average daily trading volume.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
none
-
News
Savara Announces New Employment Inducement Grant
Rhea-AI Summary
Savara Inc. (SVRA) granted inducement awards to a new employee, including options to purchase 110,000 shares of common stock and 80,000 restricted stock units. The options have a 10-year term with a vesting schedule, while the RSUs vest in full after two years of employment. The grant is pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Savara to Present at the Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
Savara Inc. (SVRA) to Participate in Fireside Chat at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
conferences
Stock SVRA logo
Savara Inc

Nasdaq:SVRA

SVRA Rankings

#2775 Ranked by Market Cap
#47 Ranked by Stock Gains
N/A Ranked by Dividends

SVRA Stock Data

700.41M
74.01M
6.17%
86.56%
2.68%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
West Lake Hills

About SVRA

savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com